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The dorsal striatum is a key node for many neurobiological processes such as motor activity, cognitive functions, and affective processes.
The proper functioning of striatal neurons relies critically on metabotropic receptors. Specifically, the main adenosine and endocannabinoid
receptors present in the striatum, ie, adenosine A2A receptor (A2AR) and cannabinoid CB1 receptor (CB1R), are of pivotal importance in
the control of neuronal excitability. Facilitatory and inhibitory functional interactions between striatal A2AR and CB1R have been reported,
and evidence supports that this cross-talk may rely, at least in part, on the formation of A2AR-CB1R heteromeric complexes. However, the
specific location and properties of these heteromers have remained largely unknown. Here, by using techniques that allowed a precise
visualization of the heteromers in situ in combination with sophisticated genetically modified animal models, together with biochemical and
pharmacological approaches, we provide a high-resolution expression map and a detailed functional characterization of A2AR-CB1R
heteromers in the dorsal striatum. Specifically, our data unveil that the A2AR-CB1R heteromer (i) is essentially absent from corticostriatal
projections and striatonigral neurons, and, instead, is largely present in striatopallidal neurons, (ii) displays a striking G protein-coupled
signaling profile, where co-stimulation of both receptors leads to strongly reduced downstream signaling, and (iii) undergoes an
unprecedented dysfunction in Huntington’s disease, an archetypal disease that affects striatal neurons. Altogether, our findings may open a
new conceptual framework to understand the role of coordinated adenosine-endocannabinoid signaling in the indirect striatal pathway,
which may be relevant in motor function and neurodegenerative diseases.
Neuropsychopharmacology (2018) 43, 964–977; doi:10.1038/npp.2017.12; published online 15 February 2017
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INTRODUCTION
The dorsal striatum is a key node for many neurobiological
processes such as motor activity, cognitive functions, and
affective processes. The vast majority (~95%) of neurons
within the striatum are GABAergic medium spiny neurons
(MSNs), which receive glutamatergic inputs primarily from
the cortex. MSNs differ in their neurochemical composition
and form two major efferent pathways, the direct (striatoni-
gral) pathway and the indirect (striatopallidal) pathway
(Kreitzer, 2009). The proper functioning of MSNs relies
critically on metabotropic receptor signaling. Many neuro-
transmitters and neuromodulators such as dopamine,
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glutamate, endocannabinoids and adenosine control MSN
activity and plasticity by engaging their cognate G protein-
coupled receptors (GPCRs) (Lovinger, 2010; Girault, 2012).
Specifically, the main endocannabinoid and adenosine
receptors present in MSNs, ie, cannabinoid type 1 receptor
(CB1R) and adenosine subtype 2A receptor (A2AR), are of
pivotal importance in the control of neuronal excitability.
CB1R is one of the most abundant GPCRs in MSNs (Glass
et al, 2000; Castillo et al, 2012). In particular, CB1R is highly
expressed in the terminals of both striatonigral and
striatopallidal MSNs, where it mediates endocannabinoid-
dependent inhibition of GABA release, thus decreasing
motor activity (Katona and Freund, 2008; Castillo et al,
2012). CB1R is also expressed in glutamatergic terminals
projecting from the cortex onto the striatum, where it
controls MSN function by blunting glutamatergic output and
mediating the so-called endocannabinoid-dependent long-
term depression (Kreitzer, 2009; Castillo et al, 2012). A2AR is
also very abundant in the striatum (Schiffmann and
Vanderhaeghen, 1993; Schiffmann et al, 2007). Presynapti-
cally, a significant fraction of the corticostriatal projections
that expresses CB1R also contains A2AR. These A2AR
molecules are mostly located on corticostriatal terminals
that form synaptic contacts with striatonigral MSNs (Quiroz
et al, 2009; Ferreira et al, 2015). Blockade of presynaptic
A2AR counteracts glutamate release and motor output
evoked by cortical stimulation (Quiroz et al, 2009; Orru
et al, 2011; Tebano et al, 2012). Postsynaptically, A2AR is
selectively located on striatopallidal MSNs, which co-express
dopamine D2 receptor (D2R) (Schiffmann et al, 2007; Azdad
et al, 2009; Tebano et al, 2012). Blockade of postsynaptic
A2AR mediates the motor-activating effects of A2AR antago-
nists, consistent with an inactivation of the indirect pathway
(Orru et al, 2011; Tebano et al, 2012).
The high expression of A2AR and CB1R in the striatum,
together with the key involvement of both receptors in the
control of motor and goal-directed behaviors, have led to a
large number of studies on the interactions between them
(Ferre et al, 2010; Tebano et al, 2012). Understanding these
interactions is of special relevance not only physiologically but
also pharmacologically as these receptors are targets of widely
consumed psychoactive substances such as caffeine (an A2AR
antagonist) and Δ9-tetrahydrocannabinol (a CB1R agonist).
Both facilitatory and inhibitory functional interactions
between striatal A2AR and CB1R have been demonstrated
(Ferre et al, 2010; Tebano et al, 2012; Justinova et al, 2014).
The precise molecular mechanisms underlying the cross-talk
between these receptors is yet to be fully understood, but some
evidence supports that they may rely, at least in part, on the
formation of A2AR-CB1R heteromeric complexes (Carriba
et al, 2007; Ferre et al, 2010; Tebano et al, 2012; Chiodi et al,
2016). Despite 410 years of research on GPCR heteromers,
there continues to be a major gap in our understanding of
where exactly heteromers are expressed as well as linking
them to precise signal transduction pathways and biological
functions. In the case of the A2AR-CB1R heteromer, factors to
consider include (i) the additional partners with which A2AR
and CB1R could interact differently at presynaptic sites (eg,
A1R) (Ciruela et al, 2006) or postsynaptic sites (eg, D2R and
mGluR5) (Navarro et al, 2008; Azdad et al, 2009; Cabello et al,
2009; Bonaventura et al, 2014; Bonaventura et al, 2015), (ii)
the convergence of adenosine and endocannabinoid actions
on various intracellular signaling pathways (Ferre et al, 2010;
Tebano et al, 2012), and (iii) the intricate network of
molecular processes controlling adenosine and endocannabi-
noid release (Kreitzer and Malenka, 2005; Lerner et al, 2010).
Previous studies on the A2AR-CB1R heteromer have relied
essentially on energy transfer-based assays in cells ectopically
expressing A2AR and CB1R, as well as co-immunolocaliz-
ation and co-immunoprecipitation experiments (Carriba
et al, 2007; Navarro et al, 2008; Bonaventura et al, 2014).
These approaches, although widely exploited and certainly
valuable, possess limitations of spatial resolution (co-immu-
nolocalization), molecular specificity (co-immunoprecipita-
tion), and biological interpretation (energy transfer using
protein overexpression) to characterize GPCR heteromers.
Hence, here we made use of techniques to allow a precise
visualization of the heteromers in situ in combination with
sophisticated genetically modified mouse models, together
with biochemical and pharmacological approaches, to
cogently characterize the anatomy and signaling profile of
the A2AR-CB1R heteromer in the dorsal striatum.
MATERIALS AND METHODS
The experimental procedures used in this study are extensively
described in Supplementary Materials and Methods. That
section provides precise details on animal models (genetic
mouse models to study the location of the A2AR-CB1R
heteromer, as well as mouse models of Huntington’s disease
(HD)), human post mortem brain samples (see also
Supplementary Table S1), recombinant adeno-associated viral
vectors, HIV TAT peptides designed to disrupt the A2AR-
CB1R heteromer, cell culture and transfection procedures,
in situ proximity ligation assays (PLA), fluorescence com-
plementation assays, dynamic mass redistribution (DMR)
label-free assays, cAMP and Ca2+ concentration assays,
western blotting assays, immunomicroscopy procedures, and
statistical analyses (see also Supplementary Table S2).
RESULTS
A2AR-CB1R Heteromers are Located on GABAergic
Neurons Rather Than Glutamatergic Projections in the
Mouse Dorsal Striatum
To clarify the precise location of A2AR-CB1R heteromers in
the dorsal striatum we conducted PLA experiments. The PLA
assay is a powerful and straightforward technique to detect
protein–protein interactions in general, and GPCR oligomers
in particular, and to localize these complexes in situ with cell
sub-population selectivity, thus allowing an unbiased demon-
stration and quantification of protein complexes in unmodi-
fied cells and tissues (Taura et al, 2015). Importantly, PLA
permits assessing close proximity between proteins within an
oligomer with high resolution (o40 nm). As PLA relies on the
amplification of a small signal, its main limitation is antibody
specificity/background noise, which we minimize by adapting
refined technical protocols as well as employing multiple
genetic mouse models and controls (Taura et al, 2015).
Here, we first used conditional mutant mice bearing a
genetic deletion of CB1R in forebrain GABAergic neurons
(CB1R
floxed/floxed;Dlx5/6-Cre/+ mice; herein referred to as GABA-
CB1R
− /− mice) or dorsal telencephalic glutamatergic neurons
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(CB1R
floxed/floxed;Nex-Cre/+ mice; herein referred to as
Glu-CB1R
− /− mice) (Monory et al, 2006). Striatal A2AR-
CB1R heteromers were evident almost exclusively as dots in
the vicinity of cell nuclei, and showed a remarkable reduction
in GABA-CB1R
− /− mice (Figure 1a and c). In contrast, no
significant differences were observed between Glu-CB1R
− /−
mice and CB1R
floxed/floxed;+/+ controls (Figure 1a and c) when
data were expressed either as a percentage of cells containing
one or more dots relative to total cell nuclei (Figure 1c) or
as a total number of dots relative to total cell nuclei
(CB1R
floxed/floxed mice: 2.23± 0.16; Glu-CB1R
− /− mice:
2.40± 0.20; n= 3 animals of each genotype). In addition,
Glu-CB1R
− /− mice did not show any significant reduction in
the percentage of A2AR-CB1R heteromer-positive cells relative
to total cell nuclei in their motor cortices (CB1R
floxed/floxed
mice: 70.3± 2.3; Glu-CB1R
− /− mice: 71.4± 3.0; n= 3 animals
of each genotype). Likewise, the expression levels of A2AR-
CB1R heteromers displayed by GABA-CB1R
− /−mice were not
decreased further when the CB1R gene was simultaneously ab-
lated in glutamatergic neurons (CB1R
floxed/floxed;Dlx5/6-Cre;Nex-Cre
mice; herein referred to as GABA-Glu-CB1R
− /− mice)
(Bellocchio et al, 2010) (Figure 1a and c). Control experiments
conducted in the absence of one of the two primary
antibodies, as well as in full CB1R
− /− mice (Marsicano et al,
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Figure 1 A2AR-CB1R heteromers are located on GABAergic neurons rather than glutamatergic projections in the mouse dorsal striatum. (a, b) PLA assays
were performed in dorsal-striatum sections from 3–4-month-old mice of different genotypes. A2AR-CB1R heteromers are shown as green dots. Nuclei are
colored in blue by DAPI staining. (a) Representative low-magnification image of tissue sections used for PLA assays. Left, DAPI-stained field; right, bright field.
Scale bar: 1 mm. Representative pictures from control CB1R-floxed, GABA-CB1R
− /−, Glu-CB1R
− /−, and GABA-Glu-CB1R
− /− mice. Scale bar: 20 μm. (b)
Representative pictures from Stop-CB1R, GABA-CB1R-RS mice, Glu-CB1R-RS mice and CB1R-RS mice. Scale bar: 20 μm. (c) Quantification of the number of
cells containing one or more dots expressed as the percentage of the total number of cells (blue nuclei). Data are the mean± SEM of counts in 5–14 different
fields from three different animals of each type. One-way ANOVA followed by Dunnet post hoc test showed a significant (*po0.05, ***po0.001) decrease
of heteromer expression compared to control CB1R-floxed mice (a) or to CB1R-RS mice (b). Further details of statistical analyses are given in Supplementary
Table S2.
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2002) and full A2AR
− /− mice (Ledent et al, 1997), provided
strong support to the specificity of the PLA analyses
performed (Supplementary Figure S1a–c). Of note, a different
anti-CB1R primary antibody provided a similar A2AR-CB1R
heteromer detection (Supplementary Figure S1d). Moreover,
the specificity of the primary antibodies used was also
demonstrated by immunocytofluorescence studies conducted
in HEK-293T cells transfected or not with cDNAs encoding
human A2AR or human CB1R (Supplementary Figure S1e).
To unequivocally ascribe A2AR-CB1R heteromers to
GABAergic neurons we made use of a Cre-mediated,
lineage-specific CB1R re-expression/rescue strategy in a
CB1R-null background (herein referred to as Stop-CB1R
mice) (Ruehle et al, 2013; De Salas-Quiroga et al, 2015). The
selective rescue of CB1R expression in forebrain GABAergic
neurons (herein referred to as GABA-CB1R-RS mice) was
achieved by expressing Cre under the regulatory elements of
the Dlx5/6 gene (De Salas-Quiroga et al, 2015). In parallel,
we rescued CB1R expression selectively in dorsal telence-
phalic glutamatergic neurons (herein referred to as Glu-
CB1R-RS mice) by using a Nex-Cre mouse line (Ruehle et al,
2013). As a control, an EIIa-Cre-mediated, global CB1R
expression-rescue in a CB1R-null background was conducted
(herein referred to as CB1R-RS mice) (Ruehle et al, 2013).
Remarkably, the expression levels of A2AR-CB1R heteromers
were notably restored in GABA-CB1R-RS mice (Figure 1b
and c). In contrast, no significant rescue of the heteromer
was observed in Glu-CB1R-RS animals when data were
expressed either as a percentage of cells containing one or
more dots relative to total cell nuclei (Figure 1c) or as a total
number of dots relative to total cell nuclei (Stop-CB1R mice:
0.24± 0.01; Glu-CB1R-RS mice: 0.28± 0.04; n= 3 animals of
each genotype).
Taken together, these data strongly support that, in the
mouse dorsal striatum, A2AR-CB1R heteromers are located on
GABAergic neurons rather than glutamatergic projections.
A2AR-CB1R Heteromers are Located on Indirect-
Pathway MSNs in the Mouse Dorsal Striatum
The vast majority (~95%) of neurons within the striatum are
MSNs (Kreitzer, 2009). These neurons differ in their
neurochemical composition and form two major efferent
pathways. The direct pathway consists of MSNs expressing
markers such as dopamine D1 receptor (D1R) and substance
P. It mainly projects to the substantia nigra pars reticulata
and the internal segment of the globus pallidus. The indirect
pathway is composed of MSNs expressing markers such as
D2R and enkephalin. It mainly projects to the external
segment of the globus pallidus, which, in turn, projects to the
subthalamic nucleus (Kreitzer, 2009). CB1R is located on
both direct-pathway and indirect-pathway MSNs, whereas
A2AR resides essentially on indirect-pathway MSNs
(Schiffmann et al, 2007; Kreitzer, 2009; Castillo et al, 2012).
As a consequence, A2AR-CB1R heteromers would conceiva-
bly be located on indirect-pathway MSNs. To substantiate
this possibility, we first used conditional mutant mice
bearing a genetic deletion of CB1R in D1R-expressing
neurons (CB1R
floxed/floxed;Drd1a-Cre/+ mice; herein referred to
as D1R-CB1R
− /− mice) (Monory et al, 2007). No differences
were observed in the expression of A2AR-CB1R heteromers,
as assessed by PLA analyses, between D1R-CB1R
− /− mice
and control mice (Supplementary Figure S2a), thus confirm-
ing that the heteromer is not located on direct-pathway
MSNs. CB1R is essentially a presynaptic receptor that, in
MSNs, resides, mainly on terminals and collaterals (Katona
and Freund, 2008; Kreitzer, 2009; Castillo et al, 2012).
Hence, we also studied the projection sites of MSNs in
CB1R
floxed/floxed mice. Specifically, we injected stereotactically
these CB1R
floxed/floxed mice with a recombinant adeno-
associated viral vector encoding Cre (or EGFP to gain
visualization of neuronal projections) into the dorsal
striatum (or the motor cortex as control). Cre expression
was driven by a CaMKIIα promoter, so it was confined to
MSNs (injections into the striatum) or principal neurons
(injections into the cortex) (Chiarlone et al, 2014).
Cre-mediated excision of the loxP-flanked CB1R gene in
dorsal-striatum MSNs of CB1R
floxed/floxed mice reduced the
expression of A2AR-CB1R heteromers in the globus pallidus
(Supplementary Figure S2b). In contrast, inactivation of the
CB1R gene in the motor cortices of CB1R
floxed/floxed mice did
not affect the expression of A2AR-CB1R heteromers on
corticostriatal inputs (Supplementary Figure S2c).
Collectively, these data show that, in the mouse dorsal
striatum, A2AR-CB1R heteromers are primarily located on
indirect-pathway MSNs.
A2AR-CB1R Heteromers Expressed in the Mouse Dorsal
Striatum are Functional
Previous reports have shown the existence of both facilitatory
and inhibitory functional interactions between A2AR and
CB1R (Ferre et al, 2010; Tebano et al, 2012). To investigate the
possible role of the A2AR-CB1R heteromer in these interac-
tions we characterized in detail heteromer functionality in the
dorsal striatum. For this purpose we used C57BL/6N-mouse
striatal slices and conducted cell signaling experiments on two
pathways coupled to A2AR and CB1R: extracellular signal-
regulated kinase (ERK) and Akt. The CB1R agonist WIN-
-55,212-2 or the A2AR agonist CGS21680 increased ERK
phosphorylation (activation) in the dorsal striatum, whereas
co-incubation with both agonists abrogated ERK phosphor-
ylation, thus demonstrating a negative cross-talk between
A2AR and CB1R (Figure 2a). In addition, the CB1R antagonist
SR141716 (rimonabant) or the A2AR antagonist ZM241385
prevented the ERK-activating effect of WIN-55,212-2 or
CGS21680 (Figure 2a). These data show a cross-antagonism
between the two receptors, a phenomenon not uncommon in
heteromers. When these cross-pharmacological assays were
conducted for Akt phosphorylation (activation), similar
negative cross-talk and cross-antagonism processes were
observed (Figure 2a). Collectively, these findings demonstrate
the existence of inhibitory interactions between A2AR and
CB1R in the mouse dorsal striatum.
Next, we sought to substantiate that the aforementioned
negative cross-talk and cross-antagonism between A2AR and
CB1R rely on A2AR-CB1R heteromers. It is generally believed
that agonist binding to the extracellular pocket of GPCRs
induces local conformational changes that increase signaling
by opening an intracellular cavity via the movement of
transmembrane helices (TMs) 5 and 6 for receptor activation,
whereas, conversely, inverse agonists decrease the basal,
agonist-independent, level of signaling by closing this cavity
(Shoichet and Kobilka, 2012; Venkatakrishnan et al, 2013). In
A2AR-CB1R heteromers in the dorsal striatum
E Moreno et al
967
Neuropsychopharmacology
050
100
150
200
pE
R
K
 (%
) 
##
** *
##
##
##
0
50
100
150
200
pA
kt
 (%
) 
***
###
#
###
##
0
50
100
150
200
250
pE
R
K
 (%
) TM5
** * ** ****
0
50
100
150
200
250
pE
R
K
 (%
) TM6 ** * * **
*
0
50
100
150
200
250
pE
R
K
 (%
) TM5 + TM6
* *
**
* *
0
50
100
150
200
250
pE
R
K
 (%
) TM7 * *
# ##
0
50
100
150
200
pA
kt
 (%
) 
TM5 * * * * *
0
50
100
150
200
pA
kt
 (%
) 
TM6** * * * *
0
50
100
150
200
pA
kt
 (%
) 
TM5 + TM6
* *
*** * *
0
50
100
150
200
250
pA
kt
 (%
) 
TM7
* *
# #
0
20
40
60
80
100
120
Fl
uo
re
sc
en
ce
(%
 o
f c
om
pl
em
en
ta
tio
n
A
2A
cY
FP
-C
B
1n
YF
P) ***
***
***
###
### *****
*** ###
pERK1/2
tERK1/2
pAkt
tERK1/2
tAkt
kDa
- 40
- 40
kDa
- 60
- 40
- 60
Figure 2 A2AR-CB1R heteromers expressed in the mouse dorsal striatum are functional. (a, c) ERK and Akt phosphorylation was determined in striatal
slices from 3–4-month-old C57BL/6N mice pre-treated for 4 h with medium (a) or with 4 μM TM5, TM6 or TM7 peptides alone or in combination (c). Slices
were then preincubated for 20 min with vehicle, the CB1R antagonist SR141716 (10 μM) or the A2AR antagonist ZM241385 (10 μM) before the addition of
vehicle, the CB1R agonist WIN-55,212-2 (1 μM), the A2AR agonist CGS21680 (1 μM) or both, for 10 min. Immunoreactive bands from 3–6 slices from 12
different animals were quantified for each condition. Values represent mean± SEM of percentage of phosphorylation relative to basal levels found in vehicle
only-treated slices (100%, dotted line). One-way ANOVA showed a significant (*po0.05, **po0.01, ***po0.001) effect over basal, or of agonist plus
antagonist treatment over agonist-only treatment (#po0.05, ##po0.01, ###po0.001). Further details of statistical analyses are given in Supplementary Table
S2. In (a), representative western blots are shown at the top of each panel. (b) Schematic representation of the bimolecular fluorescence complementation
technique showing that fluorescence only appears after the YFP Venus hemiprotein (cYFP or nYFP) complementation owing to the proximity of the two
receptors fused to hemi-YFP Venus proteins (top panel). In the bottom panel, fluorescence at 530 nm was monitored in HEK-293T cells transfected with the
indicated amounts of cDNA encoding CB1R-nYFP and A2AR-cYFP (equal amount for each construct) or, as a negative control, transfected with cDNA
encoding CB1R-nYFP and the non-interacting D1R-cYFP. Transfected cells were treated for 4 h with medium or with 4 μM TM5, TM6, and/or TM7 peptides
before fluorescence reading. Values represent mean± SEM of percentage of fluorescence relative to A2AR-cYFP/CB1R-nYFP maximal complementation
(n= 4–12 replicates from three independent experiments for each condition). One-way ANOVA showed a significant change in fluorescence over non-
transfected cells (**po0.01, ***po0.001), or of the peptide-treated over the corresponding non-peptide treated cells (###po0.001). Further details of
statistical analyses are given in Supplementary Table S2.
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fact, the reported crystal structure of the agonist-bound A2AR,
compared with the inactive, antagonist-bound A2AR, shows an
outward tilt and rotation of the cytoplasmic half of TM6 and a
movement of TM5, thus resembling the changes associated
with the active-state structure of other class A GPCRs
(Xu et al, 2011). Likewise, the crystal structure of the
antagonist-bound CB1R has been recently reported, showing
a similar opsin-like behavior for this receptor (Hua et al, 2016;
Shao et al, 2016). Our aforementioned observation that A2AR-
CB1R heteromers display both negative cross-talk and cross-
antagonism suggests a negative modulation between both
receptors through protein–protein interactions involving the
TM5/TM6 interface. Hence, to test this hypothesis, we studied
whether synthetic peptides with the sequence of TM5, TM6 or
TM7 (as negative control) of CB1R, fused to HIV TAT peptide
to allow efficient intracellular delivery and plasma membrane
insertion (Schwarze et al, 1999; He et al, 2011), were able to
disrupt A2AR-CB1R heteromerization and the observed
bidirectional cross-signaling. This approach has been recently
used by us and others to disrupt other heteromers (Guitart
et al, 2014; Lee et al, 2014; Viñals et al, 2015).
We first characterized the TM interference peptides by the
bimolecular fluorescence complementation technique. In this
assay, fluorescence only appears after correct folding of two
YFP Venus hemiproteins. This occurs when two receptors
fused to hemi-YFP Venus proteins (cYFP or nYFP) come
within proximity to facilitate YFP Venus folding (Figure 2b,
scheme). Fluorescence was detected in HEK-293T cells
transfected with different amounts of cDNA encoding
CB1R-nYFP and A2AR-cYFP, but not in negative controls
in which cells were transfected with cDNA encoding CB1R-
nYFP and the non-interacting D1R-cYFP (Figure 2b). The
TM-targeted peptides were subsequently tested. We found
that treatment of cells expressing CB1R-nYFP and A2AR-
cYFP with TM5 or TM6 (but not TM7) peptides disrupted
the heteromer structure, as revealed by a loss of fluorescence
(Figure 2b). We next studied the effect of the interference
peptides on A2AR and CB1R signaling in mouse striatal slices.
When the peptides were evaluated in cross-pharmacological
assays, we found that pretreatment of brain slices with TM5,
TM6 or both (but not TM7) peptides disrupted (i) the ability
of the CB1R agonist WIN-55,212-2 and the CB1R antagonist
SR141716 to dampen A2AR-evoked actions on ERK and Akt,
as well as (ii) the ability of the A2AR agonist CGS21680 and
the A2AR antagonist ZM241385 to dampen CB1R-evoked
actions on these two signaling pathways (Figure 2c). Of note,
when the TM5 and TM6 peptides were used in combination,
the increase in ERK and Akt phosphorylation upon receptor
co-activation tended to be higher compared with TM5-only
or TM6-only incubations (Figure 2c), thus conceivably
reflecting that the peptide combination is more efficient
than each peptide alone in disrupting the heteromer.
Together, these data provide evidence for the importance
of the TM5/TM6 interface in the A2AR-CB1R heteromer, and
support that the negative cross-talk and cross-antagonism
that occurs between CB1R and A2AR are due to protein–
protein interactions and are a specific biochemical
characteristic of the A2AR-CB1R heteromer.
Functional A2AR-CB1R Heteromers are Present in Wild-
Type and Mutant Huntingtin-Expressing Striatal
Neuroblasts
To evaluate the relevance of the A2AR-CB1R heteromer in a
pathological setting we selected HD as a model because (i) it is
the paradigmatic disease primarily caused by a selective loss of
MSNs in the dorsal striatum (Walker, 2007), and (ii) changes in
the expression and function of A2AR and CB1R have been
shown to occur in the dorsal striatum of patients and animal
models of the disease (Glass et al, 2000; Fernandez-Ruiz et al,
2011; Lee and Chern, 2014). We first characterized the
heteromer in conditionally immortalized striatal neuroblasts
expressing two normal (STHdhQ7) or mutant (STHdhQ111) full-
length endogenous huntingtin alleles with 7 or 111 glutamine
residues, respectively, which represent a widely accepted cellular
model to investigate huntingtin actions. These cells do not
exhibit mutant-huntingtin inclusions (Trettel et al, 2000), thus
allowing the modeling of changes occurring at early HD stages.
We readily detected PLA-positive A2AR-CB1R heteromers in
both STHdhQ7 and STHdhQ111 cells (Figure 3a), indicating that
the mere expression of mutant huntingtin does not prevent
heteromerization of both receptors. To evaluate the functional
characteristics of A2AR-CB1R heteromers, we first measured the
global cellular response using DMR label-free assays, which
detect changes in light diffraction in the bottom 150 nm of a
cell monolayer. In these experiments we had a preference for
CP-55,940 over WIN-55,212-2 as the CB1R agonist because the
former is less hydrophobic than the latter and so conceivably
more accessible to cultured cells. In fact, dose–response
experiments conducted in both STHdhQ7 and STHdhQ111 cells
showed that CP-55,940 impacted the DMR signal more
markedly than WIN-55,212-2 (Supplementary Figure S3a and
b). Both the A2AR agonist CGS21680 and the CB1R agonist
CP-55,940 induced time-dependent signaling in STHdhQ7 and
STHdhQ111 cells (Figure 3b). Of note, A2AR and CB1R-evoked
signaling was essentially insensitive to pertussis toxin (PTX) or
cholera toxin (CTX) (Figure 3b), thus indicating that these
receptors do not significantly couple to Gi or Gs proteins in
these cells. This notion was further supported by the
observation that, in both STHdhQ7 cells (Supplementary
Figure S4a) and STHdhQ111 cells (Supplementary Figure S4b),
neither the A2AR agonist nor the CB1R agonist was able to
affect basal or forskolin-elevated cAMP concentrations in the
absence or presence of PTX or CTX. In line with this apparent
lack of ‘classical’ A2AR-Gs/olf and CB1R-Gi coupling, the Gq
protein inhibitor YM-254890 was able to abrogate the A2AR
and CB1R-evoked changes in DMR (Figure 3c). This non-
conventional coupling did appear to be due to heteromer
formation as experiments conducted with the TM5 and TM6
peptides on STHdhQ7 and STHdhQ111 cells showed that the
peptide combination, presumably by disrupting the heteromer,
turned A2AR and CB1R action to their ‘classical’, ‘protomeric’
Gs/olf, and Gi-mediated signaling, respectively (Supplementary
Figure S4c). This strongly supports that there is no limitation of
Gs/olf or Gi protein availability in these cells, as previously
indicated by others’ work (Araki et al, 2006), and that the
A2AR-CB1R heteromer couples selectively to Gq. Moreover, and
further supporting a Gq-dependent signaling for the heteromer,
engagement of A2AR or CB1R increased intracellular free
Ca2+ concentration in both STHdhQ7 and STHdhQ111 cells
(Supplementary Figure S5).
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We next investigated whether the heteromer-specific
biochemical properties described above could influence Gq-
driven signaling. Regarding negative cross-talk, the DMR
signal induced by the A2AR agonist CGS21680 alone or the
CB1R agonist CP-55,940 alone was attenuated when both
agonists were added together to STHdhQ7 or STHdhQ111 cells
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(Figure 3d, top panels). Regarding cross-antagonism, the
DMR signal induced by the CB1R agonist was prevented not
only by the CB1R antagonist SR141716 but also by the A2AR
antagonist ZM241385, and, similarly, the DMR signal
induced by the A2AR agonist CGS21680 was also prevented
by either antagonist (Figure 3d, bottom panels). Of note, the
combination of the TM5 and TM6 peptides disrupted the
cross-antagonism between A2AR and CB1R in STHdh
Q7 and
STHdhQ111 cells (Figure 3d, bottom panels).
Collectively, these data indicate that co-expression of A2AR
and CB1R, likely through the formation of A2AR-CB1R
heteromers, facilitates Gq rather than Gs or Gi coupling in
wild-type and mutant huntingtin-expressing mouse striatal
neuroblasts.
Functional A2AR-CB1R Heteromers are Expressed in HD
Mice at Early but not Advanced Disease Stages
To study the role of A2AR-CB1R heteromers in HD in vivo
we analyzed their expression and function in a widely
accepted model of HD, heterozygous mutant knock-in
HdhQ7/Q111 mice, that express in heterozygosity a mutant
full-length huntingtin allele with 111 glutamine residues, and
wild-type HdhQ7/Q7 mice, that express two wild-type full-len-
gth huntingtin alleles with 7 glutamine residues. At an early
stage of the disease (4 months of age), mutant HdhQ7/Q111
mice displayed A2AR-CB1R heteromers in the dorsal striatum
at similar levels as wild-type HdhQ7/Q7 mice (Figure 4a).
However, at more advanced stages (6 and 8 months of age),
the expression of A2AR-CB1R heteromers was almost
completely lost in mutant HdhQ7/Q111 mice but not
wild-type HdhQ7/Q7 mice (Figure 4a). Of note, total striatal
A2AR and CB1R expression, as determined by western
blot (Supplementary Figure S6a) and immunofluorescence
microscopy (Supplementary Figure S6b), was largely pre-
served in 6-month-old mutant HdhQ7/Q111 mice compared
with age-matched wild-type HdhQ7/Q7 mice. Hence, irre-
spective of the small differences found between the western
blot and immunofluorescence data, which can be concei-
vably due to the intrinsic characteristics of the two
techniques, these findings suggest that the massive loss of
A2AR-CB1R heteromers found in Hdh
Q7/Q111 mice is mostly
heteromer-selective and not primarily due to a mere
reduction of total A2AR and CB1R molecules. In agreement
with this notion, and as a further proof of the selective loss,
the expression of another CB1R heteromer previously
reported in indirect-pathway MSNs, namely CB1R-D2R
(Navarro et al, 2008; Bonaventura et al, 2014), was not
reduced in 6-month-old mutant HdhQ7/Q111 mice compared
with their wild-type controls (Supplementary Figure S6c).
Moreover, a remarkable loss of A2AR-CB1R heteromers was
also observed in advanced stages of mouse models of HD
transgenic for human mutant huntingtin exon 1, specifically
R6/1 mice (Supplementary Figure S7a) and R6/2 mice
(Supplementary Figure S7b). Again, the expression of
CB1R-D2R heteromers, used as a control, did not decrease
in advanced-stage R6/1 or R6/2 mice compared with age-
matched wild-type animals (Supplementary Figure S7c).
CB1R is highly abundant in most MSNs (Katona and
Freund, 2008; Castillo et al, 2012), but it has been reported
that the downregulation of CB1R mRNA expression in R6
transgenic mice is striatum subregion-selective, occurring
preferentially in the dorsolateral than the dorsomedial
striatum (Denovan-Wright and Robertson, 2000; McCaw
et al, 2004). Hence, we analyzed the expression of total A2AR
and CB1R immunoreactivity, as well as that of the A2AR-
CB1R heteromer, in the dorsolateral vs the dorsomedial
striatum of wild-type HdhQ7/Q7 and mutant HdhQ7/Q111 mice
at 6 months of age. We found no significant differences
between the two dorsal-striatum compartments in total A2AR
immunoreactivity in either HdhQ7/Q7 mice (relative values:
dorsolateral: 100± 5.7; A2AR, dorsomedial: 101.8± 5.7; n= 3
animals) or HdhQ7/Q111 mice (relative values: dorsolateral:
100± 5.2; A2AR, dorsomedial: 114.8± 7.8; n= 3 animals).
There was a moderate preference of total CB1R protein
expression for the dorsolateral striatum in HdhQ7/Q7 mice
(relative values: dorsolateral: 100± 3.8; dorsomedial:
83.1± 2.5; n= 3 animals; p= 0.032), as well as a non-
significant trend in HdhQ7/Q111 mice (relative values:
dorsolateral: 100± 2.9; dorsomedial: 85.8± 2.7; n= 3 ani-
mals). Regarding the A2AR-CB1R heteromer, we found no
significant differences between the two dorsal-striatum
compartments in the percentage of heteromer-positive cells
relative to total cell nuclei in either HdhQ7/Q7 mice
(dorsolateral: 45.0± 4.9; dorsomedial: 44.0± 3.8; n= 3 ani-
mals) or HdhQ7/Q111 mice (dorsolateral: 10.4± 2.3; dorsome-
dial: 7.5± 1.4; n= 4 animals). Overall, these data show that
the A2AR-CB1R heteromer has a rather similar expression
pattern in the mouse dorsolateral and dorsomedial striatum.
To study the function of the A2AR-CB1R heteromer in HD
mice, we performed cross-signaling experiments in striatal
slices from 6-month-old HdhQ7/Q7 and HdhQ7/Q111 mice.
Consistently with the aforementioned data on both cell and
slice cultures from control C57BL/6N mice, dual agonist
treatment with WIN-55,212-2 and CGS21680 depressed
phospho-ERK or phospho-Akt signal compared with
single-agonist stimulation in wild-type HdhQ7/Q7 mice, thus
showing a negative cross-talk (Figure 4b and c). In addition,
Figure 3 A2AR-CB1R heteromers expressed in wild-type STHdh
Q7 and mutant huntingtin-expressing STHdhQ111 striatal neuroblasts signal via Gq protein
rather than Gi or Gs protein. (a) PLA assays were performed in STHdh
Q7 and STHdhQ111 cells. A2AR-CB1R heteromers are shown as green dots. Nuclei are
colored in blue by DAPI staining. Controls in the absence of anti-A2AR primary antibody were also performed. Representative pictures are shown. Scale bar:
20 μm. (b) Dynamic mass redistribution (DMR) assays were performed in STHdhQ7 and STHdhQ111 cells pretreated overnight with vehicle, pertussis toxin
(PTX; 10 ng/ml) or cholera toxin (CTX; 100 ng/ml), and further treated with vehicle, the A2AR agonist CGS21680 (1 μM) or the CB1R agonist CP-55,940
(1 μM). (c) DMR assays in STHdhQ7 and STHdhQ111 cells preincubated for 30 min with vehicle or the Gq protein inhibitor YM-254890 (1 μM), and then
activated with the A2AR agonist CGS21680 (1 μM) or the CB1R agonist CP-55,940 (1 μM). (d) DMR assays showing negative cross-talk (top panels) and cross-
antagonism (bottom panels) between A2AR and CB1R signaling. STHdh
Q7 and STHdhQ111 cells were not pre-treated (top panels) or pre-treated for 4 h with
medium (left bottom panels) or with 4 μM TM5 plus TM6 (right bottom panels) before incubation for 30 min with vehicle, the CB1R antagonist SR141716
(RIM; 1 μM) or the A2AR antagonist ZM241385 (1 μM), and then activated with vehicle, CGS21680 (1 μM) or CP-55,940 (1 μM). (b–d) The resulting shifts of
reflected light wavelength (pm) were monitored over time. Each panel is a representative experiment of n= 3 different experiments. Each curve is the mean of
a representative optical trace experiment carried out in triplicates.
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Figure 4 Functional A2AR-CB1R heteromers are expressed in Hdh
Q7/Q111 HD mice at early but not advanced disease stages. (a) PLA assays were
performed in dorsal-striatum sections from wild-type HdhQ7/Q7 mice and mutant huntingtin-expressing knock-in HdhQ7/Q111 mice. A2AR-CB1R heteromers
are shown as green dots in mice at 4, 6, and 8 months of age. Nuclei are colored in blue by DAPI staining. Representative pictures are shown. Scale bar: 20 μm.
Quantification of the number of cells containing one or more dots expressed as the percentage of the total number of cells (blue nuclei). Data are the
mean± SEM of counts in 11–26 different fields from five different animals of each type. One-way ANOVA followed by Bonferroni post hoc test showed
showed a significant (***po0.001) decrease of heteromer expression in HdhQ7/Q111compared with the respective age-matched HdhQ7/Q7 mice. (b–e) ERK
phosphorylation (b, d) and Akt phosphorylation (c, e) were determined in striatal slices from 6 month-old wild-type HdhQ7/Q7 mice (b, c) and mutant
huntingtin-expressing knock-in HdhQ7/Q111 mice (d, e). Slices were preincubated for 20 min with vehicle, the CB1R antagonist SR141716 (RIM; 1 μM) or the
A2AR antagonist ZM241385 (1 μM) before the addition of vehicle or the CB1R agonist WIN-55,212-2 (1 μM), the A2AR agonist CGS21680 (1 μM), or both,
for 10 min. Immunoreactive bands from 4–6 slices of 5–6 different animals were quantified for each condition. Values represent mean± SEM of percentage of
phosphorylation relative to basal levels found in vehicle only-treated slices (100%, dotted line). Representative western blots are shown at the top of each
panel. One-way ANOVA showed a significant effect over basal (*po0.05, **po0.01, ***po0.001), or of the antagonist plus agonist treatment over the
agonist-only treatment (#po0.05, ##po0.01, ###po0.001). Further details of statistical analyses are given in Supplementary Table S2.
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the action of both agonists was blocked when the slices
were preincubated with the partner receptor antagonists,
SR141716 or ZM241385, thus showing cross-antagonism
(Figure 4b and c). Interestingly, in HdhQ7/Q111 mice this
negative cross-talk and cross-antagonism signature was not
detected (Figure 4d and e), in line with the PLA data showing
that the A2AR-CB1R heteromer is indeed not expressed in
6-month-old HdhQ7/Q111 mice. Of note, and also in line with
Figure 5 A2AR-CB1R heteromers are lost in the caudate-putamen of high-grade HD patients. PLA assays were performed in caudate-putamen sections of
post mortem samples from control subjects (a) and HD patients at different grades (b–f). A2AR-CB1R heteromers are shown as green dots. Nuclei are colored
in blue by DAPI staining. Representative pictures are shown. Scale bar: 20 μm. (g) Quantification of the number of cells containing one or more dots expressed
as the percentage of the total number of cells (blue nuclei). Data are the mean± SEM of counts in 21–43 different fields from five control subjects, five low-
grade HD patients (1 grade 0, 2 grade 1, plus 2 grade 2) and five high-grade HD patients (2 grade 3, plus 3 grade 4). The characteristics of these human
samples are shown in Supplementary Table S1. One-way ANOVA followed by Dunnet post hoc test showed a significant (***po0.001) decrease of
heteromer expression compared to control subjects. Further details of statistical analyses are given in Supplementary Table S2. (h) Scheme depicting the
proposed location and G protein-coupling of the A2AR-CB1R heteromer in the dorsal striatum. It is currently believed (left) that the A2AR-CB1R heteromer is
located on corticostriatal projections as well as on the somatodendritic compartment of indirect-pathway MSNs. Each protomer would maintain its canonical
G protein coupling (Gs for A2AR, and Gi for CB1R). In this study we propose (middle) that the A2AR-CB1R heteromer is located mostly on indirect-pathway
MSNs, not only on their somatodendritic compartment but also likely on their terminals. According to our data, the A2AR-CB1R heteromer would facilitate Gq
rather than Gs or Gi coupling. In symptomatic HD (right), the A2AR-CB1R heteromer would be disrupted into its constituting protomers.
A2AR-CB1R heteromers in the dorsal striatum
E Moreno et al
973
Neuropsychopharmacology
the data shown above, this loss of cross-signaling did not
appear to be simply due to the loss of surface expression of
functional receptors, as the extent of single agonist-evoked
ERK and Akt stimulation was roughly equivalent in both
HdhQ7/Q111 and HdhQ7/Q7 mice (Figure 4b–e).
Together, these data demonstrate that a selective loss of
functional A2AR-CB1R heteromers accompanies disease
progression in mouse models of HD.
A2AR-CB1R Heteromers are Lost in the Caudate-
Putamen of High-Grade HD Patients
We next investigated whether the aforementioned changes in
A2AR-CB1R heteromer expression found in HD mouse
models are also evident in HD. Thus, we used the PLA
technique to analyze human caudate-putamen post mortem
samples from control subjects and HD patients at different
grades. A2AR-CB1R heteromers were readily evident in the
caudate-putamen of control individuals, with a high fraction
(~65%) of total cells expressing heteromers (Figure 5a and g,
and Supplementary Table S1). These complexes were also
detected at those normal levels in asymptomatic huntingtin
gene-mutation carriers (HD grade 0) and early symptomatic
HD patients (HD grades 1–2) (Figure 5b–d and g, and
Supplementary Table S1). In contrast, A2AR-CB1R heteromers
were strongly reduced in caudate-putamen samples from
high-grade, advanced HD patients (HD grades 3–4), with only
~ 10% of total cells containing PLA-positive dots (Figure 5e–g,
and Supplementary Table S1). PLA labeling was quite uniform
in the caudate-putamen sections analyzed, and thus no
perceptible differences in A2AR-CB1R heteromer expression
were detected between those two nuclei within each subject
(Supplementary Figure S8a and b). In addition, the demo-
graphic characteristics of the samples used indicated that the
control, low-grade HD and high-grade HD subject popula-
tions were rather homogeneous (Supplementary Table S1),
thus supporting that the differences found in A2AR-CB1R
heteromer expression were not due to those confounding
factors. Taken together, these data support that the human
brain expresses A2AR-CB1R heteromers, and suggest that these
complexes might serve specific functions that are impaired at
late stages of HD progression.
DISCUSSION
Despite the progress made toward identifying and under-
standing GPCR heteromers, their promise as precision drug
targets has yet to be fully realized due to the lack of detailed
expression maps and functional profiles. A first important
conclusion of our study refers to the precise location of the
A2AR-CB1R heteromer in the mouse dorsal striatum. The
current view in the field supports that a major site of A2AR and
CB1R colocalization is the corticostriatal-neuron terminal, at
which the two receptors could physically interact to form
A2AR-CB1R heteromers (Figure 5h). These presynaptic hetero-
mers have been suggested to provide a frame to explain, at least
in part, the negative pharmacological interactions between
A2AR and CB1R that occur in the corticostriatal pathway (Ferre
et al, 2010; Tebano et al, 2012; Ferreira et al, 2015; Chiodi et al,
2016). However, those previous studies on A2AR-CB1R
heteromers, although elegant and carefully conducted, lacked
state-of-the-art genetic controls and heteromer-detecting tech-
niques. Thus, to evaluate the possible existence of A2AR-CB1R
heteromers in corticostriatal neurons, we have made use of
three potent genetic models, namely (i) mice lacking CB1R
selectively in cortical glutamatergic neurons, (ii) CB1R-deficient
mice in which CB1R expression is selectively rescued in cortical
glutamatergic neurons, and (iii) CB1R-floxed mice in which
CB1R is selectively excised in corticostriatal neurons. Systematic
PLA assays conducted in these mouse models strikingly
showed that the expression of the A2AR-CB1R heteromer in
corticostriatal projections to the dorsal striatum is negligible
(Figure 1c). This finding supports that the inhibitory cross-talk
processes between A2AR and CB1R reported to date in
corticostriatal terminals do not rely primarily on physical
interactions between the two receptors at the plasma
membrane, but on other potential factors such us an opposite
Gs/Gi protein-dependent downstream signaling converging on
glutamate release at the presynapse, which, in turn, would
conceivably lead to an opposite modulation of the mGluR5/
phospholipase C-β/diacylglycerol lipase-α (DAGLα)/2-arachi-
donoylglycerol (2-AG) retrograde-signaling machinery at the
postsynapse (Uchigashima et al, 2007; Katona and Freund,
2008). In any case, this observed absence of presynaptic A2AR-
CB1R heteromers does certainly not preclude that A2AR and
CB1R could interact with other partners at corticostriatal
terminals to form GPCR complexes, for example, the A1R-
A2AR heteromer (Ciruela et al, 2006; Quiroz et al, 2009).
Another widely accepted site at which striatal A2AR-CB1R
heteromers are believed to reside is the somatodendritic
compartment of MSNs, the main target of corticostriatal inputs
(Carriba et al, 2007; Schiffmann et al, 2007; Ferre et al, 2010)
(Figure 5h). Here, by using (i) mice lacking CB1R selectively in
GABAergic neurons, (ii) CB1R-deficient mice in which CB1R
expression is selectively rescued in GABAergic neurons, (iii)
mice lacking CB1R selectively in D1R-expressing MSNs, and
(iv) CB1R-floxed mice in which CB1R is selectively excised in
MSNs, we cogently demonstrated that the A2AR-CB1R
heteromer is indeed present in indirect-pathway MSNs
(Figure 1 and Supplementary Figure S2). It is well established
that CB1R is largely a presynaptic receptor that is highly
abundant in the resident collaterals and long-range projections
of MSNs (Uchigashima et al, 2007; Katona and Freund, 2008).
Our data support that A2AR-CB1R heteromers are not solely
expressed in the somatodendritic compartment of indirect-
pathway MSNs, but, most likely, also at terminals of these
neurons (Figure 5h). Nonetheless, the higher PLA signal
found in GABA-CB1R
− /− and GABA-Glu-CB1R
− /−mice
compared with full CB1R
− /− mice (Figure 1c and Suppl-
ementary Figure S1c) suggests that, in the dorsal striatum,
A2AR-CB1R heteromers may also be located on non-GABAer-
gic, non-glutamatergic cells/terminals such as cholinergic
interneurons, dopaminergic projections, or astrocytes. We
are also aware that understanding the precise role of A2AR-
CB1R complexes in indirect-pathway MSNs is an extremely
complex issue. This complexity is due, in part, to the possibility
that A2AR and CB1R can interact with other receptors in
indirect-pathway MSNs. For example, A2AR is highly co-
expressed with both D2R and mGluR5, which colocalizes with
DAGLα at the perisynaptic border of dendritic spines of MSNs
(Uchigashima et al, 2007; Katona and Freund, 2008). The
activation of mGluR5 by glutamate spillover derived from
corticostriatal overactivity, which leads to DAGLα-mediated
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2-AG generation, can be tuned by D2R in MSN dendritic
spines (Kreitzer and Malenka, 2005; Yin and Lovinger, 2006).
In addition, A2AR antagonists potentiate 2-AG release and
long-term depression in indirect-pathway MSNs (Lerner et al,
2010). Whether these intricate interactions between A2AR, D2R
and mGluR5 rely, at least in part, on putative A2AR-D2R-
mGluR5 heteromers (Cabello et al, 2009) has still to be defined.
To complicate the situation further, postsynaptic A2AR and
D2R might form other higher-order heteromeric complexes,
including a proposed A2AR-CB1R-D2R heteromer (Navarro
et al, 2010; Bonaventura et al, 2014). This functional
conundrum notwithstanding, the present study provides a
cogent understanding of the anatomical distribution of the
A2AR-CB1R heteromer, or the complexes containing the
heteromer, in the corticostriatal circuit.
Our data also support that the selective coupling to Gq
protein, rather than to Gs or Gi proteins, is a biochemical
hallmark of the A2AR-CB1R heteromer in striatal cells
(Figure 5h). A G protein switch has in fact been suggested
to occur in several GPCR heteromerization processes. For
example, a change from the archetypical Gs-coupled D1R
(either as monomer or as D1R-D1R homomers) to non-
canonical Gi-coupled D1R-HT3R heteromer has been ob-
served (Ferrada et al, 2009). In addition, formation of the
CB1R-5-HT2AR heteromer may lead to a switch in G protein
coupling for 5-HT2AR from Gq to Gi protein (Viñals et al,
2015). Thus, it is possible that in a striatopallidal MSN, there
is a coexistence of A2AR and CB1R (as both monomers and
A2AR-A2AR and CB1R-CB1R homomers), which are widely
believed to couple to Gs/olf and Gi proteins, respectively,
together with A2AR-CB1R heteromers, which could couple
non-canonically to Gq protein. How these processes of GPCR
protein–protein interaction and subsequent G protein
‘shuffling’ affect corticostriatal circuitry is as yet unknown.
It is conceivable that the arrangement of the aforementioned
heteromers from A2AR and CB1R protomers in striatopallidal
MSNs, by recruiting activatory Gq proteins, would be a way
to fuel the indirect pathway and therefore blunt motor
activity. However, such a functional outcome is difficult to
predict as, according to the currently accepted models of
basal ganglia function, motor activation relies on the
simultaneous and coordinated activation of the direct and
indirect striatal pathways (Nelson and Kreitzer, 2014). In any
case, our data support the existence of different pools of
A2AR and CB1R with different G protein coupling in
corticostriatal projections, striatopallidal MSNs and striato-
nigral MSNs, thus providing adenosinergic and cannabiner-
gic cross-signaling with an extreme degree of complexity.
To study whether the A2AR-CB1R heteromer is affected in
a pathological setting we selected HD as the archetypal
neurodegenerative disease that primarily affects MSNs in a
selective manner. A significant number of studies have dealt
with CB1R expression and function in HD. In particular, a
downregulation of CB1R expression has been documented in
the caudate-putamen of HD patients and the dorsal striatum
of some HD animal models, which seems to reflect the
characteristic damage pattern of MSNs (Glass et al, 2000;
Fernandez-Ruiz et al, 2011). In addition, we (Blazquez et al,
2011) and others (Mievis et al, 2011b) have demonstrated a
neuroprotective role of CB1R in transgenic mouse models of
HD. Likewise, administration of the cannabinoid agonist
THC to HD mice prevented disease progression as assessed
by behavioral, neuropathological, and molecular markers
(Blazquez et al, 2011). In sum, it is currently believed that
CB1R may be neuroprotective in HD. Regarding A2AR, its
expression has been shown to decrease in striatopallidal MSNs
from the caudate-putamen of HD patients and the dorsal
striatum of some HD animal models (Glass et al, 2000; Lee and
Chern, 2014). However, the precise role of A2AR in HD
progression is not obvious yet, as conflicting results have been
reported. Thus, administration of the A2AR agonist CGS21680
to HDmice prevented neuropathological deficits and improved
motor alterations, although it had no effect on body weight or
lifespan (Chou et al, 2005). Likewise, the dual-function
compound T1–11, which simultaneously activates A2AR and
blocks adenosine transport, improved motor coordination
deficits, reduced striatal huntingtin aggregates, and normalized
proteasomal activity (Huang et al, 2011). Genetic ablation of
A2AR in HD mice worsened motor performance, decreased
animal survival, and reduced striatal enkephalin expression
(Mievis et al, 2011a), and also reversed working memory
deficits (Li et al, 2015). However, and in striking contrast,
administration of the A2AR antagonist SCH58261 exerted
beneficial effects in HD mice by attenuating anxiety-like
responses and sensitivity to excitotoxins, although it had no
effect on motor coordination (Domenici et al, 2007). Because
of these (at least apparently) contradictory data coming from
various A2AR gain-of-function and loss-of-function ap-
proaches, it is conceivable that A2AR can mediate different
(even opposing) molecular and physiopathological mechan-
isms depending on its cellular location and, hence, its extent of
heteromerization. It has been proposed that a selective
functional impairment of A2AR located on striatopallidal MSNs
occurs at pre-symptomatic stages of HD, whereas presynaptic
A2AR function is not affected (Orru et al, 2011). Of note, CB1R
is also lost in MSNs but not in corticostriatal projections along
HD progression (Chiodi et al, 2012; Chiarlone et al, 2014). This
suggests that the corticostriatal pool of non-heteromerizing
A2AR and CB1R would be the main target of adenosinergic and
cannabinergic drugs aimed at relieving the symptoms of HD at
late stages, whereas the MSN pool of A2AR-CB1R heteromers
could be an additional target of those drugs at early disease
stages. As A2AR-CB1R heteromers are lost in the caudate-
putamen of high-grade HD patients, the heteromer’s specific
functions would be impaired at advanced stages of HD
progression. Thus, the fine negative cross-talk between
adenosine and endocannabinoids would conceivably disappear
in advanced HD, and one might speculate that the Gq specific
signaling would be lost as well at those late disease stages
(Figure 5h). The A2AR-CB1R heteromer is singular in both its
specific localization on indirect-pathway MSNs and its
biochemical characteristics owing to its coupling to non-
canonical Gq-mediated signaling. Together, our findings may
open a new conceptual framework to understand the role of
coordinated adenosine-cannabinoid function in the indirect
striatal pathway, which may be relevant in motor function and
neural diseases.
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